He is a partner emeritus at Founders Fund, a San Francisco-based venture capital firm with over $11 billion under management.

Singerman has been a board director for several companies, including Affirm, Cloud9, Emerald Therapeutics, The Long-Term Stock Exchange, Oscar Health, and Postmates.

[7] On December 3, 2024, Singerman announced his transition to the role of partner emeritus at Founders Fund, planning to continue as a strategic advisor while prioritizing a new work-life balance.

In April 2016, AbbVie acquired Stemcentrx in a transaction valued at up to $10.2 billion, marking the largest portfolio exit in Founders Fund's history.

[9] However, in 2019, AbbVie shuttered Stemcentrx after its lead cancer drug, Rova-T, failed to outperform placebo in a Phase 3 clinical trial.